» Articles » PMID: 8502779

Lyme Disease

Overview
Publisher Elsevier
Specialty Rheumatology
Date 1993 May 1
PMID 8502779
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical features of Lyme disease have been well documented since its description as a distinct clinical entity in 1975. A better understanding of the diversity of Borrelia strains and species that cause the disease as well as new insights into the immunology and pathogenesis of Lyme disease help explain some of the observed variations in clinical manifestations. The diagnosis of Lyme disease may be straightforward when patients in endemic areas present with typical clinical features; however, the diagnosis should be in doubt when the clinical picture is nonspecific or atypical, or a feasible exposure history cannot be obtained. Laboratory diagnosis is primarily based on serologic techniques, but interpretation of test results can be fraught with uncertainty. Treatment with appropriate antibiotics is successful in the majority of cases of Lyme disease. However, some patients may not respond, and in these cases multiple repeated courses are usually ineffective and unwarranted. More data are needed to determine the appropriate treatment of Lyme disease during pregnancy, and the appropriate management of ixodes tick bites. A suitable arthropod vector and a competent animal reservoir host are essential for perpetuating Lyme disease in a geographic location. The intricate ecologic forces at work are well understood in certain endemic areas but are poorly defined elsewhere, particularly where the disease is sporadic or its existence is in question. Prevention of Lyme disease is best achieved through education regarding avoidance of the tick vector. A vaccine using a recombinant form of the OspA protein of B. burgdorferi has been successful in animal models. Whether an effective human vaccine can be developed remains unknown.

Citing Articles

Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier.

Grab D, Perides G, Dumler J, Kim K, Park J, Kim Y Infect Immun. 2005; 73(2):1014-22.

PMID: 15664945 PMC: 546937. DOI: 10.1128/IAI.73.2.1014-1022.2005.


Structural requirements for glycosaminoglycan recognition by the Lyme disease spirochete, Borrelia burgdorferi.

Leong J, Robbins D, Rosenfeld L, Lahiri B, Parveen N Infect Immun. 1998; 66(12):6045-8.

PMID: 9826395 PMC: 108771. DOI: 10.1128/IAI.66.12.6045-6048.1998.


Integrins alpha(v)beta3 and alpha5beta1 mediate attachment of lyme disease spirochetes to human cells.

Coburn J, Magoun L, Bodary S, Leong J Infect Immun. 1998; 66(5):1946-52.

PMID: 9573074 PMC: 108148. DOI: 10.1128/IAI.66.5.1946-1952.1998.


Different classes of proteoglycans contribute to the attachment of Borrelia burgdorferi to cultured endothelial and brain cells.

Leong J, Wang H, Magoun L, Field J, Morrissey P, Robbins D Infect Immun. 1998; 66(3):994-9.

PMID: 9488387 PMC: 108007. DOI: 10.1128/IAI.66.3.994-999.1998.


Predisposing factors for individuals' Lyme disease prevention practices: Connecticut, Maine, and Montana.

Herrington Jr J, Campbell G, Bailey R, Cartter M, Adams M, Frazier E Am J Public Health. 1998; 87(12):2035-8.

PMID: 9431299 PMC: 1381252. DOI: 10.2105/ajph.87.12.2035.